Skip to main content
. Author manuscript; available in PMC: 2017 Oct 7.
Published in final edited form as: Lancet Oncol. 2016 Sep 9;17(11):1558–1568. doi: 10.1016/S1470-2045(16)30366-7

Figure 3. Progression-free survival.

Figure 3

Kaplan-Meier curves for investigator-assessed disease progression (by RECIST version 1.1) at a median follow-up of 2 years in all randomised patients. 43 (45%) of 95 patients experienced an event (disease progression or death) in the combination group vs 35 (74%) of 47 patients in the ipilimumab group.